quinoxalines has been researched along with zk 200775 in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dirnagl, U; Huth, A; Jacobsen, P; McDonald, F; Neuhaus, R; Ottow, E; Schneider, HH; Sheardown, M; Turski, L; Wiegand, F | 1 |
| Groom, A; Smith, T; Turski, L; Zhu, B | 1 |
| De Keyser, J; Diener, HC; Elting, JW; Hommel, M; Kaste, M; Lees, KR; Sulter, GA; Teelken, AW; Versavel, M | 1 |
| Cebere, A; Cebers, G; Kosowski, AR; Liljequist, S; Swanhagen, AC | 1 |
| De Keyser, J; Diener, HC; Hommel, M; Kaste, M; Lees, KR; Steiner, H; Versavel, M; Walters, MR | 1 |
| Gronier, B | 1 |
| Bergholz, R; Rüther, K; Staks, T | 1 |
| Ikemoto, S; Jhou, TC; Shin, R; Vollrath-Smith, FR; Webb, SM; Xu, S | 1 |
| Li, M; Sobolevsky, AI; Yelshanskaya, MV | 1 |
| Boesen, T; Dorosz, J; Gajhede, M; Kastrup, JS; Krintel, C; Larsen, AH; Mirza, O; Thorsen, TS; Venskutonytė, R | 1 |
3 trial(s) available for quinoxalines and zk 200775
| Article | Year |
|---|---|
AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels.
Topics: Acute Disease; Aged; Area Under Curve; Biomarkers; Brain Ischemia; Dose-Response Relationship, Drug; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Humans; Male; Middle Aged; Nerve Growth Factors; Neuroglia; Organophosphonates; Phosphopyruvate Hydratase; Quinoxalines; Receptors, AMPA; Regression Analysis; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Severity of Illness Index; Stroke; Treatment Outcome | 2002 |
The AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: a double-blind, multicentre, placebo-controlled safety and tolerability study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Blood Pressure; Brain Ischemia; Electrocardiography; Humans; Middle Aged; Organophosphonates; Patient Compliance; Quinoxalines; Receptors, AMPA; Stroke; Treatment Outcome | 2005 |
Effects of the AMPA antagonist ZK 200775 on visual function: a randomized controlled trial.
Topics: Aged; Color Vision; Darkness; Electroretinography; Evoked Potentials, Visual; Humans; Male; Middle Aged; Organophosphonates; Quinoxalines; Receptors, AMPA; Vision, Ocular; Visual Acuity | 2010 |
7 other study(ies) available for quinoxalines and zk 200775
| Article | Year |
|---|---|
ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Cells, Cultured; Cerebrovascular Disorders; Craniocerebral Trauma; Evoked Potentials; Excitatory Amino Acid Antagonists; Gerbillinae; In Vitro Techniques; Mice; Neuroprotective Agents; Organophosphonates; Quinoxalines; Radioligand Assay; Rats | 1998 |
Autoimmune encephalomyelitis ameliorated by AMPA antagonists.
Topics: Animals; Brain Stem; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Excitatory Amino Acid Antagonists; Guinea Pigs; Motor Neurons; Multiple Sclerosis; Muscle Tonus; Myelin Basic Protein; Neurons; Organophosphonates; Quinoxalines; Rats; Rats, Inbred Lew; Receptors, AMPA; Receptors, Kainic Acid; Recurrence; Spinal Cord; T-Lymphocytes | 2000 |
Nicotine-induced dopamine release in the nucleus accumbens is inhibited by the novel AMPA antagonist ZK200775 and the NMDA antagonist CGP39551.
Topics: 2-Amino-5-phosphonovalerate; Animals; Cell Survival; Cells, Cultured; Cerebellum; Dopamine; Male; Microdialysis; Motor Activity; Nicotine; Nucleus Accumbens; Organophosphonates; Quinoxalines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Time Factors | 2004 |
Involvement of glutamate neurotransmission and N-methyl-d-aspartate receptor in the activation of midbrain dopamine neurons by 5-HT1A receptor agonists: an electrophysiological study in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Dizocilpine Maleate; Dopamine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; GABA Agents; Glutamic Acid; Male; Neurons; Organophosphonates; Piperazines; Prefrontal Cortex; Pyridines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Synaptic Transmission; Ventral Tegmental Area | 2008 |
Rewarding and incentive motivational effects of excitatory amino acid receptor antagonists into the median raphe and adjacent regions of the rat.
Topics: Animals; Behavior, Animal; Conditioning, Operant; Excitatory Amino Acid Antagonists; Infusions, Parenteral; Light; Male; Motivation; Motor Activity; Organophosphonates; Photic Stimulation; Pons; Quinoxalines; Raphe Nuclei; Rats; Rats, Wistar; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Reward; Self Administration; Time Factors; Vision, Ocular | 2012 |
Structure of an agonist-bound ionotropic glutamate receptor.
Topics: Animals; Cross-Linking Reagents; Crystallography, X-Ray; Cysteine; Glutamic Acid; HEK293 Cells; Humans; Ion Channel Gating; Models, Chemical; Organophosphonates; Protein Structure, Secondary; Protein Structure, Tertiary; Pyrimidinones; Quinoxalines; Rats; Receptors, AMPA | 2014 |
Binding of a negative allosteric modulator and competitive antagonist can occur simultaneously at the ionotropic glutamate receptor GluA2.
Topics: Allosteric Regulation; Animals; Benzodiazepines; Crystallography, X-Ray; Excitatory Amino Acid Antagonists; HEK293 Cells; Humans; Models, Molecular; Molecular Structure; Organophosphonates; Protein Binding; Protein Domains; Quinoxalines; Rats; Receptors, AMPA; Recombinant Proteins; Sf9 Cells; Spodoptera | 2021 |